Gilead Sciences received accelerated FDA approval for Hepcludex on May 24, 2026. Hepcludex is the first and only treatment for chronic hepatitis delta virus in the United States. This approval targets a market with high unmet medical needs.
The European CHMP issued a positive opinion for Trodelvy in first-line metastatic triple-negative breast cancer. This recommendation facilitates wider international adoption of the oncology treatment.
Gilead completed its acquisition of Tubulis to add next-generation antibody-drug conjugate assets. Analysts maintain a consensus Moderate Buy rating for the company. These developments strengthen future revenue and earnings potential.